SANA earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -3.35. Updated 2026-07-23.
Sana Biotechnology (SANA) Research Hub
Sana Biotechnology (SANA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.13 USD (-1.26%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.35, market cap 0.87B. This hub links to the full technical, earnings and options research available for SANA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.13 USD (-1.26%) |
| 52-week range | 2.74 USD – 4.19 USD |
| Trend regime | Range |
| 14-day RSI | 42.1 (Bearish) |
| Trailing P/E | -3.35 |
| Market cap | 0.87B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for SANA
Covered Call on SANA: how it works, illustrative setup around the real 3.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SANA: how it works, illustrative setup around the real 3.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SANA: how it works, illustrative setup around the real 3.13 USD price, max profit/loss, breakeven and when to use it. Educational.
SANA technical analysis: range, last 3.13 USD, RSI 42.1, 52w range 2.74 USD–4.19 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SANA in?
Sana Biotechnology (SANA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SANA in an uptrend or downtrend?
As of 2026-09-11, SANA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SANA's trailing P/E ratio?
SANA's trailing P/E is -3.35, with a market cap of 0.87B. See the earnings research page for full valuation detail.
When does SANA next report earnings?
SANA is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.15 USD.